Metabolic Disorders: Defects in Biosynthetic Pathways

Introduction

This section explores metabolic disorders arising from defects in critical biosynthetic pathways. We will focus on:

The biosynthesis of haem, including its regulation and the consequences of enzyme deficiencies (Porphyrias).
The biosynthesis of steroid hormones, with a focus on defects leading to Adrenal Hyperplasia and disorders related to testosterone metabolism (5-alpha reductase deficiency).
How understanding these biosynthetic pathways, their intermediates, and enzyme defects informs the clinical symptoms, diagnosis, and management of these disorders.

Disorders of Haem Biosynthesis: The Porphyrias

Haem is a crucial molecule, a component of haemoglobin, myoglobin, cytochromes (including cytochrome P450 enzymes), catalase, and peroxidases. Its synthesis is a complex multi-step pathway.

A. Haem Structure and Synthesis Overview:

Structure: Haem consists of a ferrous iron (Fe2+) ion chelated within protoporphyrin IX, which is made up of four pyrrole rings linked by methenyl bridges.
Precursors: Nitrogen and carbon atoms of haem are derived from glycine and succinyl CoA (succinyl-CoA is formed from acetate entering the Krebs cycle as acetyl-CoA).
Major Sites of Synthesis:
- Erythroblasts (Red Blood Cells - RBCs): Account for ~85% of total haem synthesis. Haem synthesis ceases when RBCs mature. In reticulocytes, haem stimulates protein (globin) synthesis. Regulation in RBCs occurs at the level of ferrochelatase (availability of iron) and porphobilinogen deaminase.
- Hepatocytes (Liver): The main non-RBC source. About 80% of haem produced in the liver is used for the synthesis of cytochrome P450 enzymes involved in detoxification.
Rate-Limiting Step in Liver: The formation of δ-aminolevulinic acid (ALA) from glycine and succinyl-CoA by the enzyme ALA Synthase in the mitochondria is the rate-limiting step in hepatic haem synthesis.

B. Regulation of ALA Synthase (in Liver):

Level of Enzyme Synthesis:
- Synthesis of ALA synthase and its transport to mitochondria are inhibited by elevated levels of haem and haemin (the Fe3+ oxidation product of haem). This is a key negative feedback mechanism.
- Enzyme synthesis is upregulated by many drugs (e.g., barbiturates, steroids with a 4,5 double bond like testosterone, some oral contraceptives). These drugs are metabolized by the microsomal cytochrome P450 mono-oxygenase system, a haem-containing protein system. Increased demand for cytochrome P450 leads to lower intracellular haem levels, de-repressing ALA synthase synthesis.
Level of Enzyme Activity:
- Haem and haemin directly inhibit ALA synthase activity.
- ALA synthase requires pyridoxal phosphate (Vitamin B6) as a coenzyme.

C. Porphyrias ("The Vampire Disease"):

Definition: A group of rare metabolic disorders caused by deficiencies of specific enzymes in the haem biosynthetic pathway.
Inheritance: The majority are inherited in an autosomal dominant fashion, meaning affected individuals typically have 50% of the normal enzyme activity and can still synthesize some haem.
Pathophysiology: Enzyme deficiencies lead to the accumulation of specific haem precursors (porphyrins or their precursors like ALA and porphobilinogen - PBG) proximal to the enzymatic block. These intermediates are toxic at high concentrations.
Clinical Manifestations: All haem pathway intermediates are potentially toxic. Their overproduction causes characteristic symptoms, which vary depending on the specific enzyme defect, the severity of the deficiency, and whether haem synthesis is primarily affected in the liver or developing erythrocytes (as regulation differs in these tissues). Symptoms broadly fall into two categories:
- Neurovisceral Symptoms:
  - Occasional episodes of severe neurological symptoms are associated with some porphyrias. If not treated promptly, permanent nerve damage and even death can result.
  - Elevated δ-aminolevulinic acid (ALA), due to de-repression of ALA Synthase gene transcription (resulting from low haem levels), is considered responsible for neurological symptoms.
  - Mechanisms of ALA Neurotoxicity (Proposed):
    - Structural similarity of ALA to the neurotransmitter GABA (γ-aminobutyric acid).
    - ALA autoxidation generates reactive oxygen species (ROS).
  - Haem deficiency itself may result in degenerative changes in the central nervous system.
  - Decreased haem synthesis in the liver can lead to decreased activity of hepatic tryptophan pyrrolase (a haem-dependent enzyme), potentially resulting in increased levels of serotonin and its metabolites.
- Photosensitivity:
  - A common symptom in some porphyrias where specific porphyrinogen intermediates accumulate.
  - Skin damage (blistering, scarring) can result from exposure to light.
  - This is attributable to elevated levels of light-absorbing pathway intermediates (porphyrinogens).
  - Accumulation of these intermediates results in their conversion to porphyrins by light. Porphyrins react with molecular oxygen to form ROS, which damage the skin.
Triggers for Attacks: Attacks of porphyria can be triggered by certain drugs (especially those inducing cytochrome P450), chemicals, specific foods (historically, garlic has been implicated for some types), and exposure to sunlight (in photosensitive porphyrias).
Historical/Cultural Associations: Some symptoms like photosensitivity, red teeth (in some forms), and receding gums, along with historical treatments involving blood, have led to associations with vampire folklore.

D. Acute Intermittent Porphyria (AIP):

Prevalence: Relatively common for a metabolic disorder, ranging from ~10 in 100,000 in the USA to higher incidences in Northern European countries like Sweden (60–100 per 100,000), Britain, and Ireland.
Genetics: Caused by mutations in the PBGD (Porphobilinogen Deaminase, also known as Hydroxymethylbilane Synthase) gene; inherited in an autosomal dominant fashion.
Demographics: Affects women more than men (ratio ~2:1). Most patients become symptomatic between ages 18-40 years; attacks before puberty or after 40 are unusual unless there's a major provocation.
Clinical Course: Most patients are symptom-free between attacks. The course of neurological manifestations is highly variable. Acute attacks may resolve rapidly, but sudden death can occur, possibly due to cardiac arrhythmia.
Symptoms of Acute Attacks (Neuro-visceral, No Skin Manifestations):
- Gastroenterological (most common): Colicky abdominal pain (85–95%), constipation (48–84%), vomiting (43–88%), diarrhea (5–12%).
- CNS Signs: Seizures (10–20%), mental status changes (e.g., hysteria, anxiety, depression, confusion), cortical blindness, coma.
- Peripheral Neuropathies (42–60%): Predominantly motor, can lead to muscle weakness and paralysis.
- Other: Fever (9–37%), hypertension (36–54%), tachycardia (28–80%).
Precipitants of AIP Attacks:
- Drugs: Most common precipitant, especially those that induce hepatic cytochrome P450 enzymes (e.g., barbiturates, sulphonamides). This depletes the regulatory pool of hepatic haem, leading to increased ALA synthase activity and accumulation of ALA and PBG.
- Alcohol: Excessive consumption induces hepatic cytochrome P450 enzymes.
- Tobacco Smoke: Polycyclic aromatic hydrocarbons in smoke induce hepatic cytochrome P450 enzymes and haem synthesis. An association between smoking and repeated attacks has been found.
- Infections, Surgery, and Stress.
- Reduced Energy Intake / Starvation: Dieting, postoperative periods, or concurrent illness can trigger attacks.
Treatment of AIP Attacks:
- Glucose Infusion: High carbohydrate intake helps decrease porphyrin biosynthesis in the liver (mechanism may involve repression of PGC-1α, a coactivator of ALA synthase gene expression).
- Haemin Injection: Intravenous administration of haemin (a stable form of haem) replenishes the hepatic haem pool, which represses the transcription of the ALA Synthase gene, thereby reducing the production of ALA and PBG.
- New Clinical Trials: Exploring mixtures of siRNA (to reduce ALA synthase activity) and mRNA (to increase levels of the defective PBGD enzyme).
Historical Figures: Mary Queen of Scots, King George III, and Vincent Van Gogh are among historical figures speculated to have suffered from porphyria, though these are often debated.

Disorders of Steroid Biosynthesis

Steroid hormones are synthesized from cholesterol through a series of enzymatic steps primarily in the adrenal glands and gonads.

A. Adrenal Hyperplasia (Congenital Adrenal Hyperplasia - CAH):

Definition: A group of autosomal recessive disorders characterized by defects in enzymes involved in the synthesis of cortisol, aldosterone, or both, from cholesterol in the adrenal cortex.
Prevalence: Relatively common for a metabolic disorder, around 1 in 10,000, with higher rates in some isolated communities.
Most Common Form (21-Hydroxylase Deficiency):
- Enzyme Defect: Deficiency of the enzyme 21-hydroxylase (CYP21A2).
- Consequences:
  - Lack of Cortisol: Cortisol is a key stress hormone. Its deficiency leads to a lack of negative feedback on the pituitary gland, resulting in increased ACTH (Adrenocorticotropic Hormone) secretion. Chronic ACTH stimulation causes hypertrophy (increased size) of the adrenal glands.
  - Lack of Aldosterone: Aldosterone is a mineralocorticoid crucial for sodium reabsorption in the kidney (distal tubule and collecting ducts). Its deficiency leads to salt-wasting (excessive sodium loss in urine) and potentially dehydration and hypotension.
  - Excess Androgen Production: Steroid pathway intermediates that accumulate before the 21-hydroxylase block (e.g., progesterone, 17-hydroxyprogesterone) are shunted into the androgen synthesis pathway, leading to increased production of testosterone and other androgens.
    - Females: Can lead to virilization of external genitalia (ambiguous genitalia at birth) and later issues like hirsutism, acne, and menstrual irregularities.
    - Males: May show early onset of puberty (precocious puberty).
Severity: Depends on the genotype and the degree of residual enzyme activity. Forms range from severe "classic" salt-wasting or simple virilizing CAH to milder "non-classic" or late-onset CAH.
Treatment:
- Steroid Replacement Therapy: Glucocorticoids (to replace cortisol and suppress ACTH) and often mineralocorticoids (to replace aldosterone).
- Surgical Intervention: May be required for ambiguous genitalia in females, particularly if urinary flow is impacted, or for other cosmetic/functional reasons.

B. Fetal Sexual Development and Testosterone:

Genetic Sex Determination: Determined by XY (male) or XX (female) chromosomes.
Early Development: Up until week 7-8 of pregnancy, both sexes have an undifferentiated "genital ridge". The default developmental pathway is female.
Role of Testosterone: The SRY gene on the Y chromosome triggers testis development, which then produces testosterone. Testosterone is crucial for male differentiation.
- At around week 7, in XY fetuses, testosterone levels increase significantly, peaking around week 16.
- Male sex organs begin to develop around week 9.
Dihydrotestosterone (DHT):
- Testosterone is converted to DHT by the enzyme 5-alpha reductase.
- DHT is a much more potent androgen than testosterone.
- While circulating DHT levels are about 5-10% of testosterone, in some target tissues (e.g., prostate, seminal vesicles, external genitalia, hair follicles), DHT concentrations can be much higher, and it is the primary androgen driving development and function in these tissues.
- Roles of DHT: Crucial for external male genitalia development during embryogenesis, postnatal development and maintenance of the prostate and seminal vesicles, and growth of facial/body hair. Penis growth in the third trimester is particularly dependent on DHT. Testicles typically descend around 26 weeks.
- Clinical Significance of DHT: Implicated in hirsutism (excess body hair in females), male pattern baldness, and prostate diseases like benign prostatic hyperplasia (BPH) and prostate cancer.

C. 5-Alpha Reductase Type 2 Deficiency:

Genetics: An autosomal recessive disorder affecting the SRD5A2 gene, which encodes the type 2 isoenzyme of 5-alpha reductase, predominantly found in urogenital tissues.
Prevalence: Very rare globally, but more common in some isolated communities (e.g., the "Guevedoces" of the Dominican Republic, meaning "eggs at twelve" or "penis at twelve").
Pathophysiology: Due to the deficiency of 5-alpha reductase type 2, testosterone cannot be efficiently converted to DHT in target tissues during fetal development.
Clinical Features:
- At Birth: XY individuals have ambiguous or predominantly female-appearing external genitalia (due to lack of DHT action during embryogenesis). They are often raised as girls.
- At Puberty: A significant increase in testosterone levels (from the testes, which are present and functional internally) can drive virilization. The testicles descend, and the phallus (often initially clitoris-like) grows into a small penis. Individuals often develop a male gender identity.
- Adult Features: Tend to have minimal facial hair, a small prostate, and are often infertile (though IVF may be possible).
Prostate Cancer Link and Therapeutic Implications:
- Interestingly, individuals with 5-alpha reductase type 2 deficiency have not been reported to develop prostate cancer (the most common cancer in men).
- This observation led to the development of 5-alpha reductase inhibitors (e.g., Finasteride, Dutasteride).
- These drugs are used for the treatment of BPH and androgenetic alopecia (male pattern baldness) and have been shown to reduce the risk of prostate cancer. They are also sometimes used off-label for hirsutism in females (contraindicated during pregnancy due to risk of virilizing a male fetus).

Learning Outcomes Summary

This section aimed to provide an understanding of:

How intermediates (accumulation or deficiency) influence biosynthetic pathways (e.g., ALA in porphyria, steroid precursors in CAH).
How enzyme defects (e.g., PBGD in AIP, 21-hydroxylase in CAH, 5-alpha reductase) disrupt these pathways.
How these defects lead to specific clinical symptoms (e.g., neurovisceral attacks and photosensitivity in porphyrias; virilization and salt-wasting in CAH; ambiguous genitalia in 5-alpha reductase deficiency).
How knowledge of the biosynthetic pathway, its regulation, and the specific defect informs the management and treatment of these metabolic disorders (e.g., haem/glucose for AIP; steroid replacement for CAH; 5-alpha reductase inhibitors for BPH/baldness).